CompletedPhase 1NCT01440998
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Studying Squamous cell carcinoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Robert ColemanM.D. Anderson Cancer Center
- Intervention
- Carboplatin(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2011 – 2015
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01440998 on ClinicalTrials.gov